Myeloablative radioimmunotherapy with Re-188-anti-CD66-antibody for conditioning of high-risk leukemia patients prior to stem cell transplantation: biodistribution, biokinetics and immediate toxicities - Buchmann, I; Bunjes, D; Kotzerke, J (Cancer Biother Radiopharm, 2002)
et al.